1-5 of 5
Alison J. Forgie
Close
Sort by
Journal Articles

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part

Guillermo Garcia-Manero, Amanda Przespolewski, Yasmin Abaza, Michael Byrne, Abraham P. Fong, Feng Jin, Alison J. Forgie, Athanasios C. Tsiatis, Shanhong Guan, Harry P. Erba
Journal: Blood
Blood (2022) 140 (Supplement 1): 9046–9047.
https://doi.org/10.1182/blood-2022-157606
Published: 2022
Journal Articles

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)

Guillermo Garcia-Manero, Harry P. Erba, Srinivasa R. Sanikommu, Jessica K. Altman, Hamid Sayar, Bart L. Scott, Abraham P. Fong, Shanhong Guan, Feng Jin, Alison J. Forgie, Jaume Pons, Sophia S. Randolph, Michael T. Byrne
Journal: Blood
Blood (2021) 138 (Supplement 1): 2601.
https://doi.org/10.1182/blood-2021-146547
Published: 2021
Journal Articles

ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Nehal Lakhani, MD PhD, Justin Gainor, MD, Manali Kamdar, MD, Philip Fanning, PhD, Pierre Squifflet, MSc, Feng Jin, PhD, Alison J. Forgie, PhD, Hong Wan, PhD, Jaume Pons, PhD, Sophia S Randolph, MDPhD, Won Seog Kim, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-135941
Published: 2020
Journal Articles

ALX148 Enhances the Depth and Durability of Response to Multiple AML Therapies

Amy Chen, Ons Harrabi, Abraham P Fong, MDPhD, Katherine L. Ruffner, MD, Alison J. Forgie, PhD, Janet Sim, PhD, Sophia S Randolph, MDPhD, Hong Wan, PhD, Jaume Pons, PhD, Tracy C Kuo, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–16.
https://doi.org/10.1182/blood-2020-137112
Published: 2020
Journal Articles

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Noopur S. Raje, MD, Andrzej Jakubowiak, MD PhD, Cristina Gasparetto, MD, Robert F. Cornell, MD MS, Heike I. Krupka, PhD PMP, Daniel Navarro, MD MSc, Alison J. Forgie, DPhil, Chandrasekhar Udata, PhD, Cynthia Basu, PhD, Jeffrey Chou, MD PhD, Abraham Leung, MD, Alexander M. Lesokhin, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1869.
https://doi.org/10.1182/blood-2019-121805
Published: 2019